Press Releases

Forthcoming Category lll CPT Code Reflects the Published Clinical Evidence and A Determination of Significant Value of Real-Time Fluorescence Imaging Across the Wound Care Treatment Pathway TORONTO, Nov. 4, 2019 /PRNewswire/ - MolecuLight Inc., the world's leader in handheld fluorescence imaging for real-time visualization of bact

WINNIPEG, Nov. 4, 2019 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today announced its intention to commence a substantial issuer bid (the "Offer") pursuant to which the Company will offer to purchase up to 4.0 million of its common shares (the "Common Shares") for cancellation at a set p

CHICAGO, Nov. 4, 2019 /PRNewswire/ -- Bill Gates is joining the Alzheimer's Association Part the Cloud global research grant program led by visionary philanthropist Mikey Hoag. Gates' award of $10 million will stimulate an additional $20 million

SANTA MONICA, Calif., Nov. 4, 2019 /PRNewswire/ -- PatientPop, the healthcare leader in practice growth technology, has been named Compa

SUZHOU, China and ROCKVILLE, Md., Nov. 4, 2019 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, hepatitis B virus and age-related diseases, today announced a combination therapy strategic collaboration with Henlius (2696.HK), working tog

REYKJAVIK, Iceland and SANTA CLARITA, CA, Nov. 4, 2019 /PRNewswire/ -- Jon Sigurdsson, President & CEO of Össur and John Petrovich, CEO of the Alfred Mann Foundation (AMF) recently signed a milestone agreement that allows Össur to further develop and license AMF's

STOCKHOLM, Nov. 4, 2019 /PRNewswire/ -- Calliditas Therapeutics ("Calliditas") today hosts a Capital Markets Day in Stockholm, moderated by Lars Frick from Börsveckan. The Capital Markets Day takes place at GT 30, Grev Turegatan 30 in Stockholm. The program

STOCKHOLM, Nov. 4, 2019 /PRNewswire/ -- RhoVac AB ("RhoVac") announces today, on 4th November 2019, that the first patient has been screened for the company's clinical phase IIb study in prostate cancer, a study entitled RhoVac-002 ("BRaVac"). The screening took place at the Odense University Hospital.BRaVac is a randomized, pl

SAN FRANCISCO, Nov. 4, 2019 /PRNewswire/ -- A new poll by Common Sense and SurveyMonkey found that nearly eight in 10 teens (78%)

ARLINGTON, Va., Nov. 4, 2019 /PRNewswire/ -- March of Dimes, the nation's leader in the fight for the health of all moms and babies, issued the 2019 March